Navigation Links
UIC researchers hunting drugs for devastating parasitic disease
Date:12/16/2008

Hundreds of millions of people, mainly in developing countries, are disabled by infectious diseases, according to the World Health Organization.

More than 12 million people in 88 countries are infected with leishmaniasis, a parasitic disease spread by the bite of infected sand flies. Nearly 2 million new cases are reported and about 70,000 people die from the disease annually.

Researchers at the University of Illinois at Chicago have discovered that compounds derived from a natural product can be used in developing a new drug to treat the disease.

Despite a worsening global impact of this disease, little progress has been made toward the development of new chemotherapeutics against it, says Alan Kozikowski, professor and director of UIC's Drug Discovery Program and coordinator of the project.

Drugs compounded from the toxic metal antimony have been the first-line therapeutic option for more than 50 years.

"But antimonials may cause acute pancreatitis and cardiac arrhythmia and can sometimes lead to death," Kozikowski said. Only recently, he said, have novel agents been added to the therapeutic arsenal.

Leishmaniasis can be cutaneus, which causes skin sores that leave ugly scars, or visceral, which is 100 percent fatal if left untreated.

Visceral leishmaniasis has increased in recent years due to emerging co-infections with HIV, spreading the disease to the developed countries in North America and southern Europe, Kozikowski said. The disease is normally found in tropical regions, from the rain forests in Central and South America to deserts in West Asia.

To find a starting point from which to develop a better drug, UIC postdoctoral researchers Suresh Tipparaju and Marco Pieroni synthesized a chemical "library" of more than 100 diverse compounds and screened them for biological activity against the Leishmania parasite. They observed high antiparasitic activity in a compound first isolated from streptomyces bacteria more than 20 years ago. That compound, Tipparaju said, could potentially be modified to treat leishmaniasis. It was already three times more active than miltefosine, a drug in current use, he said.

Miltefosine is the first oral drug to cure both visceral and cutaneus leishmaniasis. Despite the drug's efficacy, Tipparaju said, miltefosine is limited by its persistence in the bloodstream and long-term side effects. It is also not effective when given to patients co-infected with HIV.

The UIC researchers are attempting to develop an antiparasitic agent that is less toxic than miltefosine and that can kill the parasite inside blood cells. In addition, the researchers are investigating the mechanism of action of the new candidate compounds through a collaboration with Manlio Tolomeo of the Center for Parasitic Diseases in Palermo, Italy. Mechanistic studies could lead to further improvement of promising agents, Tipparaju said.


'/>"/>

Contact: Sam Hostettler
samhos@uic.edu
312-355-2522
University of Illinois at Chicago
Source:Eurekalert

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
4. Bipolar disorder relapses halved by Melbourne researchers
5. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
6. High and mighty: first common height gene identified by researchers behind obesity gene finding
7. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
8. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
9. Researchers develop long-lasting growth hormone
10. Jefferson immunology researchers halt lethal rabies infection in brain
11. Purdue researchers develop technology to detect cancer by scanning surface veins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... Scottsdale, Ariz. (PRWEB) , ... January 23, 2017 ... ... , recently analyzed statistics from 140 Buzzies users who entered metrics into the ... Serin's earlier clinical data. The new data showed that within just 30 seconds ...
(Date:1/24/2017)... ... ... The National Council of Alcoholism and Drug Dependence ( NCADD ), in ... designate the last full week of January as National Drug and Alcohol Facts Week. ... As a community, we can advocate for effective treatment, but also especially effective prevention ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... science companies, has achieved ISO 17100:2015 certification following a comprehensive audit performed ... the globally recognized standard that establishes guidance for critical processes within translation, ...
(Date:1/23/2017)... ... January 23, 2017 , ... The iaedp Foundation, recognized ... treatment providers who treat the full spectrum of eating disorder problems, proudly announces ... Council consists of the leading eating disorder treatments centers located throughout the U.S. ...
(Date:1/23/2017)... , ... January 23, 2017 , ... Sharon Kleyne, America’s ... air to educate listeners about the benefits of making new water infrastructure a number ... said, “it’s appropriate that we expect water infrastructure to become a top priority of ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... , Jan. 23, 2017 MouthWatch LLC announced ... was ranked as the best intraoral camera on DentalCompare,s ... the #2 spot overall. The #1 product was the ... the MouthWatch intraoral camera was "…incredibly popular because it is ... camera has a small sticker price, it doesn,t sacrifice quality ...
(Date:1/23/2017)... , Jan. 23, 2017 ... U.S. devices sold and 65% increase in consumable sales, ... DarioHealth Corp. (NASDAQ: DRIO ), a leader ... developer of the Dario™ Blood Glucose Monitoring System, an ... disruptive mobile app-based and minimally invasive smart diabetes management ...
(Date:1/23/2017)...  Delcath Systems, Inc. (NASDAQ: DCTH ), ... primary and metastatic liver cancers, today announced that ... Chief Executive Officer of Delcath will be a featured ... Annual Investor Conference at the Boca Raton Resort & ... on Tuesday, January 31, 2017 at 10:30 am Eastern ...
Breaking Medicine Technology: